GGrantIndex
Sort

23,748 grants matching melanoma

MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH

$296,550
University Of Pittsburgh At Pittsburgh · R01 · FY2000 · CA

CD24 in Cancer Resistance and Immunotherapy

$296,549
Yang Liu · Children'S Research Institute · R01 · FY2013 · CA

Genome-wide association study of cutaneous squamous cell carcinoma

$296,540
Maryam Mandana Asgari · Kaiser Foundation Research Institute · R01 · FY2013 · CA

Engineered T Cell Therapy for Melanoma

$296,514
Robert H Vonderheide · Wistar Institute · P50 · FY2014 · CA

Subcellular/Cell Cycle Boron-Delivery Studies of Unnatural Amino Acids by SIMS

$296,477
Subhash Chandra · Cornell University · R01 · FY2010 · CA

Vaccines to promote Tc-1-based targeting of tumor stroma

$296,440
Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2011 · CA

Vaccines to promote Tc-1-based targeting of tumor stroma

$296,440
Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · CA

Regulatory T Cells and Toll-Like Receptor Signaling in Lymphoma Therapy

$296,411
Wang Rongfu · Baylor College Of Medicine · P50 · FY2010 · CA

Regulation of one carbon metabolism and epigenetics by SIRT5

$296,403
David Benner Lombard · University Of Michigan At Ann Arbor · R01 · FY2018 · GM

Biospecimen and Pathology Core

$296,400
Xiaowei Xu · Wistar Institute · P50 · FY2024 · CA

Mechanism of ECM regulation of actin nucleation during morphogenesis.

$296,400
Martha C. Soto · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2009 · GM

A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma

$296,257
Stephen H Thorne · Western Oncolytics, Ltd · R44 · FY2019 · CA

Melanoma Pathogenesis

$296,222
Linda Titus-Ernstoff · Dartmouth College · R01 · FY2006 · CA

Combining targeted radionuclide therapy with a localized in situ vaccine to overcome immune suppression in the tumor microenvironment and augment T cell responses

$296,214
Paul M Sondel · University Of Wisconsin-Madison · P01 · FY2024 · CA

Resistance to apoptosis in clinical melanoma gene therapy

$296,171
Ali Jazirehi · University Of California Los Angeles · R21 · FY2012 · CA

Therapy of Melanoma with Antigen Specific T Cell Clones

$296,161
Fred Hutchinson Cancer Research Center · R21 · FY2001 · CA

The role of Mc1r in melanocytic UV-induced DNA damage and repair responses

$296,160
John A Dorazio · University Of Kentucky · R01 · FY2011 · CA

The role of Mc1r in melanocytic UV-induced DNA damage and repair responses

$296,160
John A Dorazio · University Of Kentucky · R01 · FY2012 · CA

COMMUNITY CLINICAL ONCOLOGY PROGRAM

$296,094
Evanston Northwestern Healthcare Res Ins · U10 · FY2000 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP

$296,063
Johns Hopkins University · U10 · FY2000 · CA

Mechanisms of Resistance to Radio Inducible Gene Therapy

$296,039
Ralph R Weichselbaum · University Of Chicago · R01 · FY2006 · CA

New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways

$296,039
W. Andy Tao · Purdue University · R01 · FY2014 · GM

Biomarker Discovery for the Classification of Melanoma

$295,929
Boris C Bastian · University Of California, San Francisco · R01 · FY2011 · CA

New Target Antigens for Prostate Cancer Immunotherapy

$295,926
Vaccinex, Inc. · R43 · FY2005 · CA

Understanding resistance in the HER2-HER3 tumor drive

$295,885
Mark M Moasser · University Of California, San Francisco · R01 · FY2013 · CA